Leading the way in Europe to bring
microbiome-based innovations to market.
Alliance Promotion Microbiote (APM) brings together innovative French stakeholders interested in the advancement of the microbiome industry.
APM is collectively building a dynamic ecosystem positioning France as a European leader in the development, production and marketing of scientific and therapeutic innovations linked to the microbiome.
APM gathers more than 20 key private and public players supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
APM is currently focused on advancing key topics for microbiome innovations to reach the market, clarifying the regulatory pathways for microbiome-related therapies and fostering awareness about the key role of the microbiome in health and disease.
Increase the clarity
of regulatory pathways
Foster the awareness
about the major role of the
microbiome in health and disease.
Unity is strength. Joining APM means being able to provide input to policy makers, patients’ associations, investors in Europe, and share networking opportunities while contributing to structure the industry.
MaaT Pharma Receives U.S. FDA Response
Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022.
Microbiota & Health Day 2023
Lyonbiopole proposes to broaden the field of microbiota through the theme "Bioproduction and Market Access for Microbiotic Medicinal Products?"
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota.